WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414424
CAS#: 54533-86-7 (fumarate)
Description: Nizofenone fumarate is a neuroprotective drug which protects neurons from death following cerebral anoxia (interruption of oxygen supply to the brain). It might thus be useful in the treatment of acute neurological conditions such as stroke. Nizofenone ameliorates various pathophysiologic events during ischemia, such as ATP depletion, lactate accumulation, glutamate release, free fatty acid liberation, edema, and neuronal degeneration; in particular, ischemia-induced excessive glutamate release has been completely blocked by this drug. This drug has also radical-scavenging action, comparable to vitamin E, and inhibits oxygen radical-induced lipid peroxidation. The potent cerebroprotective effect of nizofenone has been demonstrated in various experimental models of cerebral hypoxia, ischemia (focal and global), ischemia-reperfusion, and infarction. The clinical efficacy of nizofenone has been proved by pioneering double-blind studies in acute subarachnoid hemorrhage patients. Nizofenone is clinically used for preventing the delayed ischemic neurologic deficits due to late vasospasm following subarachnoid hemorrhage.
Hodoodo Cat#: H414424
Name: Nizofenone fumarate
CAS#: 54533-86-7 (fumarate)
Chemical Formula: C25H25ClN4O7
Exact Mass: 528.14
Molecular Weight: 528.946
Elemental Analysis: C, 56.77; H, 4.76; Cl, 6.70; N, 10.59; O, 21.17
Related CAS #: 54533-86-7 (fumarate salt) 54533-85-6 (free),
Synonym: Nizofenone fumarate; NSC315856; NSC-315856; NSC 315856
IUPAC/Chemical Name: Methanone, (2-chlorophenyl)(2-(2-((diethylamino)methyl)-1H-imidazol-1-yl)-5-nitrophenyl)-, trans-2-butenedioate
InChi Key: JDQAUUIBFFFOOV-WLHGVMLRSA-N
InChi Code: InChI=1S/C21H21ClN4O3.C4H4O4/c1-3-24(4-2)14-20-23-11-12-25(20)19-10-9-15(26(28)29)13-17(19)21(27)16-7-5-6-8-18(16)22;5-3(6)1-2-4(7)8/h5-13H,3-4,14H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
SMILES Code: O=C(C1=CC=CC=C1Cl)C2=CC([N+]([O-])=O)=CC=C2N3C=CN=C3CN(CC)CC.O=C(O)/C=C/C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 528.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Liu Y, Zhuang X, Gou L, Ling X, Tian X, Liu L, Zheng Y, Zhang L, Yin X. Protective effects of nizofenone administration on the cognitive impairments induced by chronic restraint stress in mice. Pharmacol Biochem Behav. 2013 Jan;103(3):474-80. doi: 10.1016/j.pbb.2012.09.009. Epub 2012 Sep 28. PubMed PMID: 23026061.
2: Nakamura T, Tsumagari T. [Effects of nizofenone on experimental arrhythmia in dogs]. Nihon Yakurigaku Zasshi. 1984 Nov;84(5):441-51. Japanese. PubMed PMID: 6097519.
3: Miura Y, Inui J, Nakamura T. [Effects of nizofenone on the action potential of guinea-pig papillary muscle and S-A node and dog Purkinje fibers]. Nihon Yakurigaku Zasshi. 1985 Mar;85(3):159-65. Japanese. PubMed PMID: 4007706.
4: Saito I, Asano T, Ochiai C, Takakura K, Tamura A, Sano K. A double-blind clinical evaluation of the effect of Nizofenone (Y-9179) on delayed ischemic neurological deficits following aneurysmal rupture. Neurol Res. 1983;5(4):29-47. PubMed PMID: 6149485.
5: Yasuda H, Izumi N, Nakanishi M, Maruyama Y. Brain protection against oxygen deficiency by nizofenone. Adv Exp Med Biol. 1988;222:403-10. PubMed PMID: 3364265.
6: Kotake H, Nawada T, Matsumoto T, Kitamura H, Kaneda T, Hasegawa J, Mashiba H. Chronotropic effect of nizofenone fumarate in rabbit sino-atrial node in vitro. Br J Pharmacol. 1988 Dec;95(4):1175-80. PubMed PMID: 3219485; PubMed Central PMCID: PMC1854257.
7: Ohta T, Kikuchi H, Hashi K, Kudo Y. Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study. J Neurosurg. 1986 Mar;64(3):420-6. PubMed PMID: 3512795.
8: Mizoi K, Olca M, Fujimoto S, Abiko H, Suzuki J. [An experimental study on the protective effect of nizofenone in cerebral ischemia]. No To Shinkei. 1984 Nov;36(11):1089-93. Japanese. PubMed PMID: 6525322.
9: Yasuda H, Nakajima A. Brain protection against ischemic injury by nizofenone. Cerebrovasc Brain Metab Rev. 1993 Winter;5(4):264-76. Review. PubMed PMID: 8110594.
10: Morimoto Y, Fukuda T, Tsumagari T. [Effects of nizofenone on ischemic cerebral edema in Mongolian gerbils]. No To Shinkei. 1984 Oct;36(10):983-8. Japanese. PubMed PMID: 6518129.
